HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $49
NovoCure Ltd. +5.41%
NovoCure Ltd. NVCR | 11.30 | +5.41% |
HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:
NVCR) with a Buy and raises the price target from $47 to $49.
